Yahoo Sports' Zach Schwartz shares his bets for the Lakers vs. Heat game.
Yahoo Sports' Zach Schwartz shares his bets for the Lakers vs. Heat game.
The Dodger postseason roster would be a good place to start. You know, the one with Justin Turner sitting front and center among all his teammates, unmasked in his full red-bearded glory. Turner’s quarantine after testing positive for COVID-19 during the clinching win over Tampa Bay ended up lasting just two innings.
Time for a TV upgrade? Walmart slashed prices on all sorts of 4K TVs from RCA and LG to Sony and Samsung—save up to a whopping $1,050.
The agreement was finalized Thursday during a meeting between Israeli Defense Minister Benny Gantz and Defense Secretary Mark Esper at the Pentagon.
Strengthen the capacity faith communities to understand the intersection of health, religion, race, and politicsRICHMOND, Va., Oct. 28, 2020 (GLOBE NEWSWIRE) -- The Balm In Gilead Inc. is a leader in bringing public health and faith communities together to strategically address health disparities in the African American community. The Balm In Gilead Inc. will use its Annual Healthy Churches 2030 Conference (HC2030) to answer this call to action by bridging faith and healthcare to breakdown health disparities in the Black community. This one-of-a-kind virtual conference will equip African American faith-based institutions and public health professionals with the tools to confront racial inequities in healthcare and wellness programs. The COVID-19 pandemic has highlighted the importance of building congregational health ministries within African American communities to offer rapid response to future public health crises. Healthy Churches 2030 Conference will examine the intersection and impact of health, religion, race, and politics on the lives of Black Americans.Addressing the alarming rates of preexisting health conditions and lack of access to qualified medical professionals in African American communities, the conference will emphasize the urgent need to create locally accessible health and wellness programs. "The Black Health Agenda for the New Decade: The Intersection of Health, Religion, Race, and Politics," the theme for this year's conference, embodies the immediate need to confront health disparities and create prevention models within the Black community.Participants will hear directly from some of the nation's top public health officials, medical professionals, and faith leaders. This year's Healthy Churches 2030 Conference speakers include: * Dr. Freda Lewis-Hall, Ph.D.; Clinician, Educator, Researcher, and Leader in Biopharmaceuticals and Life Sciences Industries * Dr. Kafui Dzirasa, Ph.D.; Assistant Professor and Resident Physician, Laboratory for Psychiatric Neuroengineering, Department of Psychiatry and Behavioral Sciences, Center for Neuroengineering, Duke University Medical Center * Rev. Dr. Delman L. Coates, Ph.D.; Pastor of Mt. Ennon Baptist Church in Clinton, MD. * Rev. Dr. Shively T. J. Smith Ph.D.; Assistant Professor of New Testament at Boston University School of Theology * Dr. LaPrincess C. Brewer, MPH; Assistant Professor of Medicine, Mayo Clinic College of Medicine, Rochester MN * Dr. Sam Dagogo-Jack, D.Sc.; Professor of Medicine & Chief, Division of Endocrinology, Diabetes and Metabolism, University of Tennessee Health Science Center, Memphis, TN * Dr. Keith C. Ferdinand, FACC, FAHA, FNLA, FASCP; Professor of Medicine at the Tulane University School of Medicine * Fred Hammond; Grammy award-winning artist, vocalist, songwriter, musician, producer, and arranger.Speakers and presenters will share strategies, resources, and tools to strengthen the capacity of congregational health ministries across the United States to increase health prevention, disease management, and participation in clinical trials. "By building a nationwide network of health ministries within African American churches, The Balm In Gilead is actively diversifying the healthcare delivery model by transforming churches into local health hubs," said Dr. Pernessa C. Seele, founder and CEO of The Balm In Gilead, Inc. The upcoming Healthy Churches 2030 Conference also features content from our elite sponsors. Diamond sponsors AARP, Alnylam Pharmaceuticals Inc., Amgen Inc., Biogen Inc., Janssen Pharmaceuticals Inc., Silver sponsors Astellas Pharma Inc., Pfizer Rare Disease, Roche, and Bronze sponsor Mayo Clinic.This year, the annual conference offers group registration at $25 per person for groups of twenty or more and $75 for individuals. Registration for this year's virtual conference closes November 9, 2020. To register and learn more about the conference, visit healthychurches2030.org.About Healthy Churches Conference 2030 Healthy Churches 2030 (HC2030) is an annual conference designed to bridge faith and public health and address health disparities among African American communities. Healthy Churches 2030 Conference is the only nationally recognized conference that provides vital learnings and capacity development through training on healthcare models, nutrition, funding opportunities, and evaluation presented by leaders in scientific research, clinicians skilled in nutritional medicine, including experts on food and healthcare innovation. To learn more, visit healthychurches2030conference.org.About The Balm In Gilead, Inc. Founded in 1989, The Balm In Gilead, a not-for-profit, non-governmental organization, has developed an international reputation for providing an insightful understanding of religious cultures, values, and extraordinary abilities to build strong, trusted partnerships with faith communities throughout the world. By working with national, regional, and local faith-based partners, we establish grass-roots health delivery systems and increase the number of individuals who have the knowledge to lead in areas of health promotion, disease prevention, screening, and disease management. To learn more, visit balmingilead.org.Contacts: Alysia Gradney The Gudz Principal 832-263-1714 email@example.com
A man convicted of first-degree murder in the 2018 shooting death of a Chicago police commander was sentenced Wednesday to life in prison. Shomari Legghette, 47, received a mandatory life term for the fatal shooting of 53-year-old Cmdr. Paul Bauer because he was convicted of killing a police officer in the line of duty. Bauer was walking to City Hall on Feb. 13, 2018, when he heard a radio call that a man was running from officers.
The Dodgers third baseman returned to the field and removed his mask to celebrate the team's World Series win — after testing positive during the game.
"Design Home" is more than just a phone game.
EXCLUSIVE: Cavalry Media has optioned the rights to Morgan Housel’s recently published International Bestseller, The Psychology of Money: Timeless lessons on wealth, greed, and happiness from Harriman House publishers. Money—investing, personal finance, and business decisions—is typically taught as a math-based field, where data and formulas tell us exactly what to do. But in the real world […]
Popular TikToker Shubha Vedula shows us what it would be like if Céline Dion sang ‘Savage’.
(Bloomberg) -- Brazil held its benchmark interest rate unchanged at a record low and reaffirmed plans to keep it there for the foreseeable future despite concerns about inflation and government overspending.The central bank, led by its President Roberto Campos Neto, on Wednesday kept the benchmark Selic steady at 2% for the second straight meeting, as forecast by all 37 economists in a Bloomberg survey. Policy makers halted their monetary easing cycle last month after lowering borrowing costs by 450 basis points.Policy makers said conditions for their forward guidance on low rates continue to hold, with inflation expectations “significantly below” target. “The current fiscal regime has not been changed; and long-term inflation expectations remain well anchored,” they wrote in a statement.The central bank introduced its forward guidance in August when it signaled plans to keep borrowing costs at a record low as long as inflation expectations remain below target. Since then, Brazil’s interest rate curve has steepened as traders price in bets of rate increases starting as soon as January.“Even as the economy is recovering faster than its peers, it still needs the rates at a very stimulative level,” Luciano Rostagno, chief strategist at Banco Mizuho, said before the decision. “Inflation is still benign despite recent shocks.”Latin America’s largest economy is staging an uneven recovery with the help of substantial monetary and fiscal stimulus implemented during the coronavirus crisis, including billions of dollars in cash handouts to informal workers and loans to struggling companies.Retail sales are booming, but the overall services sector is mired in a slowdown and unemployment is poised to surge to an all-time high. Moreover, an initial rebound seen in the third quarter is likely to lose steam by year-end as the government phases out at least part of the emergency aid. Inflation remains below target but has been accelerating with a jump in food and fuel costs.Fiscal UncertaintyUncertainty related to how much of the fiscal stimulus will remain in place in 2021 and how the government will pay for it has become the main concern in local financial markets, driving inflation expectations higher and leading investors to bet interest rates will have to go up sooner rather than later.The government is spending this year some $57 billion on monthly stipends that, while keeping vulnerable Brazilians afloat during the pandemic, have pushed the country’s finances to the brink of a crisis. Top policy makers including Campos Neto and Economy Minister Paulo Guedes have called for a return to belt-tightening measures as public debt nears 100% of gross domestic product.Read More: Brazil’s Coronavirus Splurge Is Sparking a Rebellion in Markets“The major risk going forward is fiscal, and if the government can’t come back to the austerity plan, the Brazilian real would weaken too much and the forward guidance of holding rates couldn’t be sustained,” said Rostagno.(Adds statement from central bank in third paragraph.)For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.
Combination Enhances Syneos Health’s Industry-Leading Position Across Fast-Growing Small to Mid-Sized CategoryMORRISVILLE, N.C., Oct. 28, 2020 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization combining a CRO (Contract Research Organization) and a CCO (Contract Commercial Organization), today announced an agreement to acquire Synteract, a full-service CRO focused on the rapidly growing emerging biopharma segment. Synteract has built a leading reputation among emerging biopharma, providing deep therapeutic expertise in oncology, rare and orphan diseases, neuroscience, dermatology, and pediatrics. Synteract’s client base comprises primarily pre-revenue companies, a segment in which Syneos Health has growth opportunities. Synteract’s 700 employees across North America, Europe, Asia Pacific and Africa have supported more than 4,000 Phase I-IV clinical trials across 26,000 sites in more than 60 countries.The acquisition will enhance Syneos Health’s leading position in the marketplace, particularly for serving customers across the small to mid-sized (SMID) category – further diversifying the Company’s customer base and expanding support to the high-growth pre-revenue segment. According to industry estimates, funding to the biotech sector has shown no signs of slowing down, remaining near all-time record highs. Syneos Health continues to experience strong SMID demand with double digit year-over-year pipeline growth.The transaction provides significant revenue synergy opportunities, as Syneos Health brings scale and new capabilities to Synteract’s unique customer base while maintaining Synteract’s laser-focus on the emerging biopharma segment. Building on Syneos Health’s track record of delivering cost synergies, the Company will also leverage its global infrastructure and integration expertise to optimize operational efficiencies and drive improved margins.Upon the transaction closing, Synteract will maintain its brand, led by strong management, operating as a Syneos Health Business Unit.“Synteract is one of the leading mid-sized, late-stage-focused CRO platforms with global reach and an attractive focus on the highest growth customer segment in the CRO space fueled by near-record funding levels,” said Alistair Macdonald, Chief Executive Officer, Syneos Health. “With Synteract, we will strengthen our leadership across the entire SMID category while we continue to drive growth among large biopharma customers. Importantly, we share operating and cultural philosophies built around finding the best combination of product, process and technology to fuel innovation. I look forward to welcoming Synteract to the Syneos Health family, as we collectively work to change patients’ lives.”For Synteract customers seeking alternatives to traditional product development and commercialization options, they will also have access to Syneos One™, providing comprehensive end-to-end capabilities to maximize asset value.“Joining Syneos Health combines our emerging biopharma expertise and expands our differentiated delivery model,” said Steve Powell, Chief Executive Officer, Synteract. “We are excited to join the Syneos Health team, as they provide increased global scale, service breadth and the technology infrastructure that will drive continued growth. On behalf of our management team, I thank our dedicated employees and customers who have made this combination possible, as well as Amulet Capital Partners for their significant support as an investor over the last several years.”The Company expects to close the transaction by the end of 2020, subject to the satisfaction of customary closing conditions.Latham & Watkins LLP is serving as legal advisor to Syneos Health. Jefferies LLC is serving as exclusive financial advisor to Synteract, and Skadden, Arps, Slate, Meagher & Flom LLP is serving as legal advisor.About Syneos Health Syneos Health® (Nasdaq:SYNH) is the only fully integrated biopharmaceutical solutions organization. The Company, including a Contract Research Organization (CRO) and Contract Commercial Organization (CCO), is purpose-built to accelerate customer performance to address modern market realities. We bring together approximately 24,000 clinical and commercial minds with the ability to support customers in more than 110 countries. Together we share insights, use the latest technologies and apply advanced business practices to speed our customers’ delivery of important therapies to patients. To learn more about how we are shortening the distance from lab to life®, visit syneoshealth.com or subscribe to our podcast.About Synteract “Bringing Clinical Trials to Life” represents Synteract’s commitment to engage with drug developers, patients, investigators, and regulatory experts, to bring insights to action and make better therapies a reality. Synteract supports biotech and pharma companies across all phases of drug development with multi-disciplinary teams and deep expertise. Synteract has conducted nearly 4,000 studies on six continents in over 62 countries. Synteract offers notable depth of expertise in oncology, dermatology, general medicine, infectious disease and vaccine, neuroscience, pediatrics, and rare and orphan diseases. Connect on LinkedIn and Twitter.Forward Looking Statements Except for historical information, all of the statements, expectations, and assumptions contained in this press release are forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, including the benefits of our acquisition of Synteract, the closing of our acquisition of Synteract and the source of funding for such acquisition, and our foundation for growth. Actual results might differ materially from those explicit or implicit in the forward-looking statements. Important factors that could cause actual results to differ materially include, but are not limited to: risks related to the satisfaction of the closing conditions of the Synteract acquisition, risks associated with acquired businesses, including the ability to integrate acquired operations, products, and technologies in our business; risks associated with the Company's acquisition strategy; failure to realize the full value of goodwill and intangible assets; restructuring risk; and other risk factors set forth in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2019 as updated by the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2020, and other SEC filings, copies of which are available free of charge on the Company's website at investor.syneoshealth.com. The Company assumes no obligation and does not intend to update these forward-looking statements, except as required by law.ContactsSyneos HealthInvestor Relations: Ronnie Speight Senior Vice President, Investor Relations +1 919 745 2745 firstname.lastname@example.orgPress/Media: Danielle DeForge Vice President, External Communications +1 202 210 5992 email@example.comSynteractPress/Media: Joakim Lindroos Vice President, Marketing +1 514 947 2033 firstname.lastname@example.org
Emotions were still running high Wednesday in the neighborhood in and around where 27-year-old Walter Wallace Jr. was fatally shot by police.
NEW YORK, Oct. 28, 2020 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP reminds investors that a class action lawsuit has been filed in the U.S. District Court for the Eastern District of New York on behalf of those who acquired Nano-X Imaging Ltd. (“Nano-X” or the “Company”) (NASDAQ: NNOX) securities during the period from August 21, 2020 through September 15, 2020 (the “Class Period”). Investors have until November 16, 2020 to apply to the Court to be appointed as lead plaintiff in the lawsuit. According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) Nano-X’s commercial agreements and its customers were fabricated; (2) Nano-X’s statements regarding its “novel” Nano-X System were misleading as the Company never provided data comparing its images with images from competitors’ machines; (3) Nano-X’s submission to the U.S. Food and Drug Administration (“FDA”) admitted the Nano-X System was not original; and (4) as a result, defendants’ public statements were materially false and/or misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.If you acquired Nano-X securities, have information, or would like to learn more about these claims, please contact Thomas W. Elrod of Kirby McInerney at 212-371-6600, by email at email@example.com, or by filling out this contact form, to discuss your rights or interests with respect to these matters without any cost to you.Kirby McInerney is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, and whistleblower litigation. The firm’s efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars. Additional information about the firm can be found at Kirby McInerney’s website: www.kmllp.com.This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.ContactsKirby McInerney LLP Thomas W. Elrod, Esq., (212) 371-6600 firstname.lastname@example.org www.kmllp.com
The former Waukegan police officer who fatally shot a Black teen and wounded a Black woman last week turned on his body camera after the shooting.
The Mets also declined options for the 2021 season on Robinson Chirinos and Todd Frazier.
NEW YORK, Oct. 28, 2020 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP reminds investors that a class action lawsuit has been filed in the U.S. District Court for the District of Michigan on behalf of those who acquired Credit Acceptance Corporation (“Credit Acceptance” or the “Company”) (NASDAQ: CACC) securities during the period from November 1, 2019 through August 28, 2020, inclusive (the “Class Period”). Investors have until December 1, 2020 to apply to the Court to be appointed as lead plaintiff in the lawsuit. According to the Complaint, the Company made false and misleading statements to the market. Credit Acceptance used high-risk loans to top off loan pools that it packaged and securitized. The Company made subprime loans at high interest rates to borrowers it knew could not repay them. The Company’s hidden finance charges raised the interest rate of these loans above the usury rate ceiling set by state law. The Company used aggressive and illegal measures to collect debt from its defaulted borrowers. Based on these facts, the Company’s public statements were false and materially misleading throughout the class period. When the market learned the truth about Credit Acceptance, investors suffered damages.If you acquired Credit Acceptance securities, have information, or would like to learn more about these claims, please contact Thomas W. Elrod of Kirby McInerney at 212-371-6600, by email at email@example.com, or by filling out this contact form, to discuss your rights or interests with respect to these matters without any cost to you.Kirby McInerney is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, and whistleblower litigation. The firm’s efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars. Additional information about the firm can be found at Kirby McInerney’s website: www.kmllp.com.This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.ContactsKirby McInerney LLP Thomas W. Elrod, Esq., (212) 371-6600 firstname.lastname@example.org www.kmllp.com
HOW DID WE NOT THINK OF THIS BEFORE?
The U.S. Justice Department vastly expanded its inquiry Wednesday into whether New York is undercounting coronavirus deaths among nursing home residents, demanding detailed data from hundreds of private facilities. The demand ratchets up pressure on Democratic Gov. Andrew Cuomo after months of bipartisan criticism that the state’s official tally of 6,722 dead at long-term care facilities is probably off by thousands. Cuomo's administration has repeatedly refused to release such nursing home data to lawmakers and the media, including a public-records request from The Associated Press dating back to May.
We're obsessed!From House Beautiful
SACRAMENTO, Calif., Oct. 28, 2020 (GLOBE NEWSWIRE) -- Pacific Ethanol, Inc. (NASDAQ: PEIX), a leading producer of specialty alcohols and essential ingredients, today announced the closing of its previously announced underwritten public offering of common stock and pre-funded warrants and concurrent private offering of warrants, for total gross proceeds of approximately $75.0 million. The company closed an underwritten public offering of 5,075,000 shares of its common stock at a public offering price of $8.42 per share and 5-year pre-funded warrants to purchase 3,825,493 shares of common stock at a public offering price of $8.42 per pre-funded warrant. In addition, in a concurrent private placement, the company also issued to investors, for a nominal price, warrants to purchase an additional 8,900,493 shares of common stock at an exercise price of $9.757 per share. The warrants will become exercisable after the six-month anniversary of the offering and will expire on the 18-month anniversary of the offering. The aggregate gross proceeds from the offerings of common stock, pre-funded warrants and warrants was approximately $75.0 million. The net offering proceeds to the company were approximately $70.0 million after deducting underwriting discounts and commissions and other estimated offering expenses.The company intends to use the net proceeds from the offering to reduce debt and other corporate purposes. Repaying a portion of the company’s senior notes and term loans, which have interest rates of 15% and 7%, respectively, using proceeds from the equity offering is expected to be accretive to 2020 earnings per share on a pro forma basis.Michael Kandris, the company’s president and CEO, stated “The net proceeds from this capital raise significantly accelerates improving the company’s balance sheet and allows us to focus our resources on highly valuable and profitable initiatives. We are excited about our company’s future with this improved liquidity, reduced debt burden, and strong financial performance.”Guggenheim Securities LLC acted as the sole book-running manager for the public offering. Craig-Hallum Capital Group LLC and H.C. Wainwright & Co. LLC acted as co-managers for the public offering.A prospectus supplement and accompanying prospectus describing the terms of the public and private offering has been filed with the SEC. Copies of the final prospectus supplement and the accompanying prospectus relating to the securities being offered may also be obtained, when available, from Guggenheim Securities LLC, Attention: Syndicate Prospectus Department, 330 Madison Avenue, New York, NY 10017, or by telephone at (212) 518-9658 or by email at GSEquityProspectusDelivery@guggenheimpartners.com. Electronic copies of the final prospectus supplement and accompanying prospectus are available on the SEC’s website at http://www.sec.gov.About Pacific Ethanol, Inc. Pacific Ethanol, Inc. (PEIX) is a leading producer of specialty alcohols and essential ingredients. The company is focused on products for four key markets: Health, Home & Beauty, Food & Beverage, Essential Ingredients and Renewable Fuels. The company’s customers include major food and beverage companies and consumer products companies. Pacific Ethanol’s subsidiary, Kinergy Marketing LLC, markets all specialty alcohol products for Pacific Ethanol’s distilleries as well as fuel grade ethanol for third parties. Pacific Ethanol’s subsidiary, Pacific Ag. Products LLC, markets wet and dry distillers grains. For more information please visit www.pacificethanol.com.Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995 Statements and information contained in this communication that refer to or include Pacific Ethanol’s estimated or anticipated future results or other non-historical expressions of fact are forward-looking statements that reflect Pacific Ethanol’s current perspective of existing trends and information as of the date of the communication. Forward looking statements generally will be accompanied by words such as “anticipate,” “believe,” “plan,” “could,” “should,” “estimate,” “expect,” “forecast,” “outlook,” “guidance,” “intend,” “may,” “might,” “will,” “possible,” “potential,” “predict,” “project,” or other similar words, phrases or expressions. Such forward-looking statements include, but are not limited to, statements concerning future market conditions; Pacific Ethanol’s new business focus and its effects; Pacific Ethanol’s expectation that by using a portion of the net proceeds from the offerings to repay a portion of Pacific Ethanol’s senior notes and term loans will be accretive to 2020 earnings per share on a pro forma basis;; Pacific Ethanol’s expectations regarding its current and future financial performance; and Pacific Ethanol’s other plans, objectives, expectations and intentions. It is important to note that Pacific Ethanol’s plans, objectives, expectations and intentions are not predictions of actual performance. Actual results may differ materially from Pacific Ethanol’s current expectations depending upon a number of factors affecting Pacific Ethanol’s business. These factors include, among others, adverse economic and market conditions, including for specialty alcohols and essential ingredients; export conditions and international demand for the company’s products; fluctuations in the price of and demand for oil and gasoline; raw material costs, including production input costs, such as corn and natural gas; the effects – both positive and negative – of the novel coronavirus; and the ability of Pacific Ethanol to timely and successfully execute on its strategic realignment and new business focus. These factors also include, among others, the inherent uncertainty associated with financial and other projections; the anticipated size of the markets and continued demand for Pacific Ethanol’s products; the impact of competitive products and pricing; the risks and uncertainties normally incident to the specialty alcohol production and marketing industries; changes in generally accepted accounting principles; successful compliance with governmental regulations applicable to Pacific Ethanol’s distilleries, products and/or businesses; changes in laws, regulations and governmental policies; the loss of key senior management or staff; and other events, factors and risks previously and from time to time disclosed in Pacific Ethanol’s filings with the Securities and Exchange Commission including, specifically, those factors set forth in the “Risk Factors” section contained in Pacific Ethanol’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 13, 2020.Company IR Contact:IR Agency Contact:Media Contact: Pacific Ethanol, Inc.Moriah ShiltonPaul Koehler 916-403-2755LHAPacific Ethanol, Inc. Investorrelations@pacificethanol.com415-433-3777916-403-2790 email@example.com